氧化剂诱导肾脏预适应的机制:Nrf2依赖、P21非依赖的抗衰老通路
该研究在CD-1小鼠中比较了缺血预适应(IPC)与氧化剂诱导预适应(OIP)对P21、细胞衰老及缺血性急性肾损伤的影响。IPC诱导持久P21激活和肾小管衰老;OIP不上调P21、增加细胞增殖、避免衰老,并通过激活Nrf2通路显著保护缺血性急性肾衰竭。
要点
- IPC诱导持久P21活化并导致肾小管衰老。
- OIP不诱导P21,增加增殖标志物,避免衰老状态。
- OIP通过激活Nrf2通路保护缺血性急性肾损伤。
核心结论
- OIP激活细胞保护性Nrf2通路而非P21通路,抑制缺血后P21诱导和肾脏衰老,并显著保护缺血性急性肾损伤。
研究设计与样本
- CD-1小鼠接受IPC(5-15分钟)或OIP策略(锡原卟啉诱导血红素加氧酶抑制±亲本铁给药),评估P21诱导、细胞增殖、肾脏衰老及对缺血性急性肾损伤的抵抗。
主要发现
- IPC诱导剧烈(10-25倍)且持久的P21激活和下游肾小管衰老。
- OIP未上调P21,增加而非减少细胞增殖标志物,并避免衰老状态。
- OIP显著抑制缺血诱导的P21上调,抑制缺血后衰老发展,并提供近乎完全的缺血性急性肾衰竭保护。
- OIP在4小时内激活三个经典Nrf2调控基因(NQO1、SRXN1、GCLC;mRNA增加3-5倍),该激活在Nrf2-/-小鼠中缺失,且Nrf2-/-小鼠未出现显著OIP介导的缺血性急性肾衰竭保护。
关键数值与推荐
- P21诱导评估包括mRNA和蛋白水平;细胞增殖用KI-67和磷酸化组蛋白H3核染色;衰老评估包括P16ink4a、P19Arf mRNA和衰老相关β-半乳糖苷酶水平。
- Nrf2激活通过NQO1、SRXN1、GCLC的mRNA增加(3-5倍)评估。
临床怎么用
- OIP可能是一种临床可行的方法,安全激活Nrf2通路,从而提供对临床肾损伤的保护。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: P21, a cyclin kinase inhibitor, is upregulated by renal 'ischemic preconditioning' (IPC), and induces a 'cytoresistant' state. However, P21-induced cell cycle inhibition can also contribute to cellular senescence, a potential adverse renal event. Hence, this study assessed whether: (i) IPC-induced P21 upregulation is associated with subsequent renal senescence; and (ii) preconditioning can be established 'independent' of P21 induction and avoid a post-ischemic senescent state? METHODS: CD-1 mice were subjected to either IPC (5-15 min) or to a recently proposed 'oxidant-induced preconditioning' (OIP) strategy (tin protoporphyrin-induced heme oxygenase inhibition +/- parental iron administration). P21 induction [messenger RNA (mRNA)/protein], cell proliferation (KI-67, phosphohistone H3 nuclear staining), kidney senescence (P16ink4a; P19Arf mRNAs; senescence-associated beta-galactosidase levels) and resistance to ischemic acute kidney injury were assessed. RESULTS: IPC induced dramatic (10-25×) and persistent P21 activation and 'downstream' tubular senescence. Conversely, OIP did not upregulate P21, it increased, rather than decreased, cell proliferation markers, and it avoided a senescence state. OIP markedly suppressed ischemia-induced P21 up-regulation, it inhibited the development of post-ischemic senescence and it conferred near-complete protection against ischemic acute renal failure (ARF). To assess OIP's impact on a non-P21-dependent cytoprotective pathway, its ability to activate Nrf2, the so-called 'master regulator' of endogenous cell defenses, was assessed. Within 4 h, OIP activated each of three canonical Nrf2-regulated genes (NQO1, SRXN1, GCLC; 3- to 5-fold mRNA increases). Conversely, this gene activation pathway was absent in Nrf2-/- mice, confirming Nrf2 specificity. Nrf2-/- mice also did not develop significant OIP-mediated protection against ischemic ARF. CONCLUSIONS: OIP (i) activates the cytoprotective Nrf2, but not the P21, pathway; (ii) suppresses post-ischemic P21 induction and renal senescence; and (iii) confers marked protection against ischemic ARF. In sum, these findings suggest that OIP may be a clinically feasible approach for safely activating the Nrf2 pathway, and thereby confer protection against clinical renal injury.
引用
- Johnson ACM, Zager RA. Mechanisms and consequences of oxidant-induced renal preconditioning: an Nrf2-dependent, P21-independent, anti-senescence pathway. Nephrol Dial Transplant. 2018. PMID: 29522116. doi:10.1093/ndt/gfy029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。